Switch to:
More From Other Websites
aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the... May 15 2017
Atyr Pharma reports 1Q loss May 11 2017
aTyr Pharma Announces First Quarter 2017 Operating Results May 11 2017
aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular... Apr 24 2017
aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in... Apr 24 2017
aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors Apr 10 2017
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors Apr 03 2017
aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference Mar 29 2017
aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived... Mar 15 2017
aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy... Mar 03 2017
aTyr Pharma Rises 16% on Orphan Drug Status Mar 01 2017
aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference Mar 01 2017
aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular... Feb 28 2017
High court ruling limits international reach of patent laws Feb 22 2017
Atyr Pharma Stock Spikes 33% on FDA Updates Jan 19 2017
FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B... Jan 18 2017
Roberts recuses from patent case after discovering conflict Jan 04 2017
Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares Dec 21 2016
Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers? Dec 16 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK